Shield Therapeutics achieving significant milestones
Shield Therapeutics (STX) detailed a series of achievements in its FY19 business update. The highlights included a 67% increase in sales volumes in European markets and, notably, FDA approval of Feraccru (Accrufer) with the broadest possible label to treat iron deficiency with or without anaemia. It also delivered a post-period announcement of an attractive licensing deal with ASK Pharm in China. The very positive body of clinical data, and the product profile, position Accrufer to challenge market incumbents in US, an addressable market worth up to $2bn, whilst the deal with ASK Pharm improves the company’s financial, strategic and commercial prospects and opens the door to China, the world’s second largest pharma market.
Quick facts: Shield Therapeutics PLC
Price: 94.99 GBX
Market Cap: £111.32 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE